Atlas Trials

Janssen Pharmaceutical K.K.

127 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Janssen Pharmaceutical K.K.

RecordFirmDate
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis (NCT06295692)Janssen Pharmaceutical K.K.2024-02-09
A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa (NCT05926583)Janssen Pharmaceutical K.K.2023-09-12
A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer (NCT05567185)Janssen Pharmaceutical K.K.2023-03-03
A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension (NCT05167825)Janssen Pharmaceutical K.K.2022-11-14
A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants (NCT05242432)Janssen Pharmaceutical K.K.2022-04-01
A Study of JNJ-75105186 in Healthy Japanese and Chinese Participants (NCT05159128)Janssen Pharmaceutical K.K.2021-11-15
A Study of JNJ-77242113 in Healthy Japanese and Chinese Participants (NCT05062200)Janssen Pharmaceutical K.K.2021-10-25
A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer (NCT04945733)Janssen Pharmaceutical K.K.2021-08-30
An Observational Study of Japanese Participants With X-linked Retinitis Pigmentosa (NCT04868916)Janssen Pharmaceutical K.K.2021-07-26
A Study of Symptom Improvement of Ulcerative Colitis After an Induction Dose of Ustekinumab in Japanese Clinical Practice (NCT04963725)Janssen Pharmaceutical K.K.2021-07-18
A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma (NCT04773522)Janssen Pharmaceutical K.K.2021-05-20
A Study of JNJ-67953964 in Healthy Japanese Adult Male Participants (NCT04791332)Janssen Pharmaceutical K.K.2021-04-30
A Registry Study of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in Japan (NCT04459507)Janssen Pharmaceutical K.K.2021-03-22
A Study of Guselkumab in Participants With Systemic Sclerosis (NCT04683029)Janssen Pharmaceutical K.K.2021-02-24
A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma (NCT04696809)Janssen Pharmaceutical K.K.2021-02-22
A Study of JNJ-61393215 in Healthy Japanese Male Participants (NCT04713930)Janssen Pharmaceutical K.K.2021-01-29
A Study of JNJ-40411813 in Healthy Japanese Male Participants (NCT04677530)Janssen Pharmaceutical K.K.2021-01-29
A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD) (NCT04630145)Janssen Pharmaceutical K.K.2021-01-08
A Study of Ad26.COV2.S in Adults (COVID-19) (NCT04509947)Janssen Pharmaceutical K.K.2020-08-11
A Study of Macitentan, in Healthy Japanese Male Participants (NCT04500808)Janssen Pharmaceutical K.K.2020-07-21
A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (NCT04397263)Janssen Pharmaceutical K.K.2020-06-10
A Study to Evaluate the Single Vaccination of an Adenovirus Serotype 26 Pre-Fusion F (Ad26.preF) Based Respiratory Syncytial Virus (RSV) Vaccine in Japanese Adults Aged 60 Years and Older (NCT04354480)Janssen Pharmaceutical K.K.2020-05-15
A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (NCT04325828)Janssen Pharmaceutical K.K.2020-04-07
A Study to Evaluate the Different Doses of VAC52416 (ExPEC10V) in Japanese Adults (NCT04306302)Janssen Pharmaceutical K.K.2020-03-13
A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM) (NCT04062448)Janssen Pharmaceutical K.K.2019-09-25
A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan (NCT04034095)Janssen Pharmaceutical K.K.2019-07-08
A Study of JNJ-64530440 in Healthy Japanese Male Participants (NCT03915886)Janssen Pharmaceutical K.K.2019-04-15
A Study of JNJ-63733657 in Healthy Japanese Participants (NCT03689153)Janssen Pharmaceutical K.K.2018-09-28
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers (NCT03547037)Janssen Pharmaceutical K.K.2018-08-31
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Subcutaneous (SC) Injections of JNJ-64565111 in Healthy Male Japanese Participants and to Assess Pharmacokinetics Following Subcutaneous Injections of JNJ-64565111 in Healthy Male Caucasian Participants (NCT03618160)Janssen Pharmaceutical K.K.2018-08-06
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Guselkumab Following a Single Intravenous Administration in Healthy Japanese Participants (NCT03536325)Janssen Pharmaceutical K.K.2018-05-31
A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD) (NCT03474679)Janssen Pharmaceutical K.K.2018-05-01
Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) (NCT02895815)Janssen Pharmaceutical K.K.2018-04-09
A Study to Assess the Nicotine Pharmacokinetics, Tolerability and Safety With a New Oral Nicotine Replacement Product in Healthy Japanese Smokers (NCT03398876)Janssen Pharmaceutical K.K.2017-12-22
Next →

Track Janssen Pharmaceutical K.K. automatically

Every clearance here is in the API, with alerts when new ones post.